Montelukast

Montelukast, the active ingredient in this product, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children as prescribed by a healthcare professional to manage symptoms.

GNH USA supplies this product as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation and allergic responses. - Asthma: improves control of persistent asthma and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible. Common Side Effects: - Headache: mild to moderate intensity, often transient. - Upper respiratory tract infection: symptoms such as sore throat, nasal congestion or mild fever. - Abdominal pain: discomfort in the stomach area, may be intermittent. - Diarrhea: loose stools, usually self‑limiting. - Cough: occasional dry cough without fever. Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis requiring immediate medical attention. - Mood changes: depression, anxiety, or suicidal thoughts reported in rare cases. - Hepatotoxicity: elevated liver enzymes or hepatitis, monitored by liver function tests. - Angioedema: rapid swelling of face, lips or tongue, potentially airway‑obstructing. - Blood disorders: eosinophilia or neutropenia, identified through blood counts.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Assess asthma control: confirm that the patient’s asthma is not well‑controlled with inhaled therapy alone. - Monitor for neuropsychiatric events: watch for mood changes, depression or suicidal thoughts. - Evaluate liver function: consider baseline liver enzymes in patients with hepatic disease. - Use caution in children: pediatric dosing requires careful adjustment and monitoring. - Review concomitant medications: check for potential interactions that may alter efficacy. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Montelukast can interact with other medicines, affecting its effectiveness or safety. Major Interactions (Avoid): - Rifampin: a potent CYP3A4 inducer that can markedly lower montelukast plasma concentrations, reducing clinical efficacy. - Phenobarbital: hepatic enzyme inducer that may decrease montelukast levels, potentially compromising asthma control. Moderate Interactions (Monitor Closely): - Ketoconazole: strong CYP3A4 inhibitor that can increase montelukast exposure, requiring observation for enhanced effects. - Fluconazole: moderate inhibitor of CYP3A4 that may raise montelukast levels slightly; monitor for side effects. - Warfarin: occasional reports of altered International Normalized Ratio; check coagulation status when initiating or stopping montelukast. - Antidepressants (SSRIs): possible additive neuropsychiatric effects; observe patients for mood changes or suicidal ideation.